Atrial Fibrillation (AF)NCT07808307
Tele-Rehabilitation After Catheter Ablation in Patients With Atrial Fibrillation
A study testing Remotely Supervised Cardiac Telerehabilitation in people with Atrial Fibrillation (AF), run by Hande Cörüt at 1 site in Turkey (Türkiye).
Trial summary
This study aims to investigate the effects of remotely supervised cardiac telerehabilitation in patients with atrial fibrillation who have undergone catheter ablation. Participants will be randomly assigned to a cardiac telerehabilitation group or a control group. Read more about this study
- Who is it for?
- Ages 50 to 70 years
- Conditions the study is for
- Atrial Fibrillation (AF)
- What is being tested?
- Remotely Supervised Cardiac Telerehabilitation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Sep 2026to Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 50-75 years.
- Diagnosed with atrial fibrillation and treated with catheter ablation.
- Have a smartphone or computer compatible with the digital equipment provided for the study.
- Have access to the Internet.
- Provide written informed consent to participate in the study.
Who cannot join
- Presence of a non-cardiovascular condition (orthopedic or neurological) that limits participation in exercise.
- Acute heart failure, cancer, or worsening of a comorbid condition within the previous 3 months that may affect the assessment or intervention.
- Severe cognitive impairment.
- Unwillingness to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Dokuz Eylul University Hospital
Izmir, Balçova, 35330
About this study
Official title: Effects of Remotely Supervised Cardiac Tele-Rehabilitation in Patients With Atrial Fibrillation After Catheter Ablation: A Single-Blind Randomized Controlled Trial
This study aims to investigate the effects of remotely supervised cardiac telerehabilitation in patients with atrial fibrillation who have undergone catheter ablation. Participants will be randomly assigned to a cardiac telerehabilitation group or a control group. The telerehabilitation group will receive a 12-week remotely supervised exercise program in addition to standard care, consisting of aerobic, strengthening, and stretching exercises. The control group will receive standard care and general exercise guidance without an individualized exercise program. Functional exercise capacity, muscle strength, arterial stiffness, heart rate variability, quality of life, physical activity, balance, cognitive function, anxiety and depression, and atrial fibrillation recurrence will be evaluated.
Read the detailed description
This is a single-blind, randomized controlled study involving patients with atrial fibrillation who have undergone catheter ablation. Participants meeting the eligibility criteria will be informed about the study and will provide written informed consent before participation.
Participants will be randomly allocated to either a remotely supervised cardiac telerehabilitation group or a control group. The cardiac telerehabilitation group will receive standard care plus a 12-week remotely supervised exercise program consisting of aerobic, strengthening, and stretching exercises. The program will be performed three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes.
Aerobic exercise will initially be performed at moderate intensity, corresponding to 40-60% of heart rate reserve according to the Karvonen method and a perceived exertion of 4-6 on the Modified Borg Scale. Exercise intensity and duration will be progressively increased according to individual tolerance. Strengthening exercises will be performed using elastic resistance bands, with exercise intensity monitored using the Modified Borg Scale.
Exercise sessions will be conducted remotely by a physiotherapist using synchronous video-conferencing platforms or applications. Participants will use a Polar H10 chest heart rate sensor and a sports watch during exercise sessions. Exercise data will be uploaded to the PolarBeat platform and monitored remotely by the physiotherapist.
The control group will receive standard care and general information regarding the benefits of exercise and appropriate physical activity recommendations. Participants in the control group will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program.
Assessments will include functional exercise capacity, muscle strength, handgrip strength, arterial stiffness, heart rate variability, anxiety and depression, atrial fibrillation-specific quality of life, physical activity, balance and fall risk, cognitive function, and atrial fibrillation recurrence. Adherence to the telerehabilitation program will also be recorded.
- Conditions
- Atrial Fibrillation (AF)
- Being tested
- Remotely Supervised Cardiac Telerehabilitation, Usual Care and General Exercise Guidance
- Keywords
- Atrial Fibrillation, Catheter Ablation, Cardiac Telerehabilitation, Remote Exercise Training, Exercise Capacity, Cardiac Rehabilitation
- Medical subject headings
- Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Remotely Supervised Cardiac TelerehabilitationBehavioural
A 12-week remotely supervised cardiac telerehabilitation exercise program consisting of aerobic, strengthening, and stretching exercises. Participants will exercise three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes. Exercise intensity will be individually prescribed and progressed according to participant tolerance.
Usual Care and General Exercise GuidanceOther
Participants will receive standard care and general exercise guidance. They will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program.
| Study group | Role | What they receive |
|---|---|---|
| Cardiac Telerehabilitation Group | Experimental | Participants in this group will receive standard care plus a 12-week remotely supervised cardiac telerehabilitation exercise program consisting of aerobic, strengthening, and stretching exercises. The program will be performed three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes. Receives: Behavioral: Remotely Supervised Cardiac Telerehabilitation |
| Control Group | Active comparator | Participants in this group will receive standard care and general exercise guidance. They will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program. Receives: Other: Usual Care and General Exercise Guidance |
What is being measured
The primary outcome is the main question the study is designed to answer.
6 Minute Walk Test (6MWT) Distance
Distance walked during the 6-minute walk test, measured in meters, as an indicator of functional exercise capacity.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Secondary outcomes (23)
Muscle Strength
Maximum isometric muscle strength will be assessed using a hand-held dynamometer. Bilateral knee extension, shoulder flexion, shoulder abduction, elbow flexion, and elbow extension strength will be measured; the best value will be recorded in kilograms.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Handgrip Strength
Handgrip strength will be assessed using a Jamar hand dynamometer. Measurements will be performed three times for each hand at 5-second intervals, and the best value will be recorded in kilograms.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Arterial Stiffness-Carotid-Femoral Pulse Wave Velocity (cfPWV)
Carotid-Femoral Pulse Wave Velocity (cfPWV)
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Arterial Stiffness-Augmentation Index (AIx)
Augmentation Index (AIx) will be assessed noninvasively using the SphygmoCor XCEL device and reported as a percentage (%).
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability-SDNN
SDNN(ms) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - RMSSD
RMSSD(ms) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - Low-Frequency Power (LF)
Low-frequency (LF) power(ms²) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - High-Frequency Power (HF)
High-frequency (HF) power(ms²) will be assessed using a Polar H10 heart rate sensor and Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - LF/HF Ratio
The LF/HF ratio will be calculated using Kubios HRV software from a 3-minute resting recording obtained with the participant in the supine position.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Atrial Fibrillation-Specific Quality of Life
The Atrial Fibrillation Effect on Quality-of-Life Questionnaire (AFEQT) will be used to assess atrial fibrillation-specific health-related quality of life. The total score ranges from 0 to 100, with higher scores indicating better health-related quality of life.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Physical Activity Level
Physical activity level will be objectively assessed using a pedometer. Participants will wear the sensor during all waking hours, except during showering and swimming, for 7 consecutive days. Daily step counts and sensor wearing times will be recorded in an activity diary. Physical activity will be assessed during the first 7 days after baseline assessment and during the final 7 days following completion of the 12-week intervention.
Measured: During the first 7 days after baseline assessment (1 week after catheter ablation) and during the final 7 days after completion of the 12-week intervention
HADS-Anxiety
The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A) will be used to assess anxiety symptoms. The score ranges from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
HADS - Depression
The depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) will be used to assess depressive symptoms. The score ranges from 0 to 21, with higher scores indicating greater depressive symptom severity
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Cognitive Function
Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The MoCA evaluates attention and concentration, executive functions, memory, language, visuospatial skills, abstraction, calculation, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Atrial Fibrillation Recurrence
Atrial fibrillation recurrence will be assessed by a cardiologist using 12-lead electrocardiography and 24-hour Holter monitoring. Atrial fibrillation recurrence will be defined as documented atrial fibrillation lasting more than 30 seconds.
Measured: Throughout the 12-week intervention period, when clinically indicated
Telerehabilitation Program Adherence
Adherence to the telerehabilitation program will be calculated as the percentage of completed exercise sessions out of the 36 prescribed sessions. Participants will be categorized according to session attendance as adherent (>80%), partially adherent (20%-80%), or non-adherent (<20%).
Measured: Throughout the 12-week intervention period
M-CTSIB - Sway Index, Eyes Open on Firm Surface
Sway Index will be assessed during the eyes-open condition on a firm surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Closed on Firm Surface
Sway Index will be assessed during the eyes-closed condition on a firm surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Open on Foam Surface
Sway Index will be assessed during the eyes-open condition on a foam surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Closed on Foam Surface
Sway Index will be assessed during the eyes-closed condition on a foam surface using the Modified Clinical Test of Sensory Interaction on Balance (M-CTSIB) performed on the Biodex Balance System. Higher Sway Index values indicate greater postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Overall Stability Index
Overall Stability Index will be assessed using the Postural Stability Test performed on the Biodex Balance System. Higher values indicate greater postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Anterior/Posterior Stability Index
Anterior/Posterior Stability Index will be assessed using the Postural Stability Test performed on the Biodex Balance System. Higher values indicate greater anterior-posterior postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Medial/Lateral Stability Index
Medial/Lateral Stability Index will be assessed using the Postural Stability Test performed on the Biodex Balance System. Higher values indicate greater medial-lateral postural sway and poorer postural stability.
Measured: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2026
- Study startSep 2026 (estimated)
- Primary completionJun 2027 (estimated)
- Study completionJun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Atrial Fibrillation (AF)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to either a remotely supervised cardiac telerehabilitation group or a control group. The telerehabilitation group will receive a 12-week exercise program in addition to standard care, while the control group will receive standard care and general exercise guidance without an individualized exercise program.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 28 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hande Cörüt
- Sponsor type
- University, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Responsible party
- Sponsor-investigator, Hande Cörüt, Dokuz Eylul University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07808307
- Sponsor's protocol ID
- DEU-AF-TELEREHAB-01
- Status last verified
- Sep 2026
- First submitted
- 27 Aug 2026
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15-25. doi: 10.1161/CIRCEP.110.958033. Epub 2010 Dec 15.
PubMed 21160035Schaffarczyk M, Rogers B, Reer R, Gronwald T. Validity of the Polar H10 Sensor for Heart Rate Variability Analysis during Resting State and Incremental Exercise in Recreational Men and Women. Sensors (Basel). 2022 Aug 30;22(17):6536. doi: 10.3390/s22176536.
PubMed 36081005Misra S, Niazi K, Swayampakala K, Blackmon A, Lang M, Davenport E, Saxonhouse S, Fedor J, Powell B, Thompson J, Holshouser J, Mehta R. Outcomes of a Remote Cardiac Rehabilitation Program for Patients Undergoing Atrial Fibrillation Ablation: Pilot Study. JMIR Cardio. 2023 Dec 14;7:e49345. doi: 10.2196/49345.
PubMed 38096021Cai C, Bao Z, Wu N, Wu F, Sun G, Yang G, Chen M. A novel model of home-based, patient-tailored and mobile application-guided cardiac telerehabilitation in patients with atrial fibrillation: A randomised controlled trial. Clin Rehabil. 2022 Jan;36(1):40-50. doi: 10.1177/02692155211032372. Epub 2021 Jul 16.
PubMed 34266323Kato M, Ogano M, Mori Y, Kochi K, Morimoto D, Kito K, Green FN, Tsukamoto T, Kubo A, Takagi H, Tanabe J. Exercise-based cardiac rehabilitation for patients with catheter ablation for persistent atrial fibrillation: A randomized controlled clinical trial. Eur J Prev Cardiol. 2019 Dec;26(18):1931-1940. doi: 10.1177/2047487319859974. Epub 2019 Jul 5.
PubMed 31272205
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Remotely Supervised Cardiac Tele-Rehabilitation in Patients With Atrial Fibrillation After Catheter Ablation: A Single-Blind Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07808307
- Acronym / sponsor ID
- DEU-AF-TELEREHAB-01
- Conditions
- Atrial Fibrillation (AF)
- Keywords
- Atrial Fibrillation, Catheter Ablation, Cardiac Telerehabilitation, Remote Exercise Training, Exercise Capacity, Cardiac Rehabilitation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 28 participants (estimated)
- Lead sponsor
- Hande CörütUniversity, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Study start
- Sep 2026 (estimated)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2027 (estimated)
- First posted
- 8 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the effects of remotely supervised cardiac telerehabilitation in patients with atrial fibrillation who have undergone catheter ablation. Participants will be randomly assigned to a cardiac telerehabilitation group or a control group. The telerehabilitation group will receive a 12-week remotely supervised exercise program in addition to standard care, consisting of aerobic, strengthening, and stretching exercises. The control group will receive standard care and general exercise guidance without an individualized exercise program. Functional exercise capacity, muscle strength, arterial stiffness, heart rate variability, quality of life, physical activity, balance, cognitive function, anxiety and depression, and atrial fibrillation recurrence will be evaluated.
Detailed description
This is a single-blind, randomized controlled study involving patients with atrial fibrillation who have undergone catheter ablation. Participants meeting the eligibility criteria will be informed about the study and will provide written informed consent before participation.
Participants will be randomly allocated to either a remotely supervised cardiac telerehabilitation group or a control group. The cardiac telerehabilitation group will receive standard care plus a 12-week remotely supervised exercise program consisting of aerobic, strengthening, and stretching exercises. The program will be performed three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes.
Aerobic exercise will initially be performed at moderate intensity, corresponding to 40-60% of heart rate reserve according to the Karvonen method and a perceived exertion of 4-6 on the Modified Borg Scale. Exercise intensity and duration will be progressively increased according to individual tolerance. Strengthening exercises will be performed using elastic resistance bands, with exercise intensity monitored using the Modified Borg Scale.
Exercise sessions will be conducted remotely by a physiotherapist using synchronous video-conferencing platforms or applications. Participants will use a Polar H10 chest heart rate sensor and a sports watch during exercise sessions. Exercise data will be uploaded to the PolarBeat platform and monitored remotely by the physiotherapist.
The control group will receive standard care and general information regarding the benefits of exercise and appropriate physical activity recommendations. Participants in the control group will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program.
Assessments will include functional exercise capacity, muscle strength, handgrip strength, arterial stiffness, heart rate variability, anxiety and depression, atrial fibrillation-specific quality of life, physical activity, balance and fall risk, cognitive function, and atrial fibrillation recurrence. Adherence to the telerehabilitation program will also be recorded.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned to either a remotely supervised cardiac telerehabilitation group or a control group. The telerehabilitation group will receive a 12-week exercise program in addition to standard care, while the control group will receive standard care and general exercise guidance without an individualized exercise program.
| Arm | Type | Receives |
|---|---|---|
| Cardiac Telerehabilitation Group | Experimental | Behavioral: Remotely Supervised Cardiac TelerehabilitationParticipants in this group will receive standard care plus a 12-week remotely supervised cardiac telerehabilitation exercise program consisting of aerobic, strengthening, and stretching exercises. The program will be performed three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes. |
| Control Group | Active comparator | Other: Usual Care and General Exercise GuidanceParticipants in this group will receive standard care and general exercise guidance. They will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program. |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Aged 50-75 years.
- Diagnosed with atrial fibrillation and treated with catheter ablation.
- Have a smartphone or computer compatible with the digital equipment provided for the study.
- Have access to the Internet.
- Provide written informed consent to participate in the study.
Key exclusion criteria (4 listed)
- Presence of a non-cardiovascular condition (orthopedic or neurological) that limits participation in exercise.
- Acute heart failure, cancer, or worsening of a comorbid condition within the previous 3 months that may affect the assessment or intervention.
- Severe cognitive impairment.
- Unwillingness to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Remotely Supervised Cardiac TelerehabilitationA 12-week remotely supervised cardiac telerehabilitation exercise program consisting of aerobic, strengthening, and stretching exercises. Participants will exercise three days per week for a total of 36 sessions, with each session lasting approximately 45-60 minutes. Exercise intensity will be individually prescribed and progressed according to participant tolerance. | Behavioural | Cardiac Telerehabilitation Group |
| Usual Care and General Exercise GuidanceParticipants will receive standard care and general exercise guidance. They will be encouraged to achieve 150 minutes of moderate physical activity per week but will not receive an individualized exercise training program. | Other | Control Group |
Primary outcome
6 Minute Walk Test (6MWT) Distance
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Distance walked during the 6-minute walk test, measured in meters, as an indicator of functional exercise capacity.
23 secondary outcomes
Muscle Strength
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Handgrip Strength
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Arterial Stiffness-Carotid-Femoral Pulse Wave Velocity (cfPWV)
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Arterial Stiffness-Augmentation Index (AIx)
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability-SDNN
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - RMSSD
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - Low-Frequency Power (LF)
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - High-Frequency Power (HF)
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Heart Rate Variability - LF/HF Ratio
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Atrial Fibrillation-Specific Quality of Life
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Physical Activity Level
Time frame: During the first 7 days after baseline assessment (1 week after catheter ablation) and during the final 7 days after completion of the 12-week intervention
HADS-Anxiety
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
HADS - Depression
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Cognitive Function
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Atrial Fibrillation Recurrence
Time frame: Throughout the 12-week intervention period, when clinically indicated
Telerehabilitation Program Adherence
Time frame: Throughout the 12-week intervention period
M-CTSIB - Sway Index, Eyes Open on Firm Surface
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Closed on Firm Surface
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Open on Foam Surface
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
M-CTSIB - Sway Index, Eyes Closed on Foam Surface
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Overall Stability Index
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Anterior/Posterior Stability Index
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Postural Stability - Medial/Lateral Stability Index
Time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Results publication: PubMed 21160035Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15-25. doi: 10.1161/CIRCEP.110.958033. Epub 2010 Dec 15.
- Results publication: PubMed 36081005Schaffarczyk M, Rogers B, Reer R, Gronwald T. Validity of the Polar H10 Sensor for Heart Rate Variability Analysis during Resting State and Incremental Exercise in Recreational Men and Women. Sensors (Basel). 2022 Aug 30;22(17):6536. doi: 10.3390/s22176536.
- Results publication: PubMed 38096021Misra S, Niazi K, Swayampakala K, Blackmon A, Lang M, Davenport E, Saxonhouse S, Fedor J, Powell B, Thompson J, Holshouser J, Mehta R. Outcomes of a Remote Cardiac Rehabilitation Program for Patients Undergoing Atrial Fibrillation Ablation: Pilot Study. JMIR Cardio. 2023 Dec 14;7:e49345. doi: 10.2196/49345.
- Results publication: PubMed 34266323Cai C, Bao Z, Wu N, Wu F, Sun G, Yang G, Chen M. A novel model of home-based, patient-tailored and mobile application-guided cardiac telerehabilitation in patients with atrial fibrillation: A randomised controlled trial. Clin Rehabil. 2022 Jan;36(1):40-50. doi: 10.1177/02692155211032372. Epub 2021 Jul 16.
- Results publication: PubMed 31272205Kato M, Ogano M, Mori Y, Kochi K, Morimoto D, Kito K, Green FN, Tsukamoto T, Kubo A, Takagi H, Tanabe J. Exercise-based cardiac rehabilitation for patients with catheter ablation for persistent atrial fibrillation: A randomized controlled clinical trial. Eur J Prev Cardiol. 2019 Dec;26(18):1931-1940. doi: 10.1177/2047487319859974. Epub 2019 Jul 5.
- Individual participant dataSharing planned: Undecided
Related trials for Atrial Fibrillation (AF)
Active, not recruiting
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
Paroxysmal AF
Active, not recruiting
CONVERGE Post-Approval Study (PAS)
Chronic Atrial Fibrillation
RecruitingPhase 2
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Atrial Fibrillation (AF)
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruitingObservational study
Hummingbird ICE Study
ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION, Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Remotely Supervised Cardiac Telerehabilitation in people with Atrial Fibrillation (AF), run by Hande Cörüt at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hande CORUT, PhD Student (+90 0507 664 15 15, handedincel@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
6 Minute Walk Test (6MWT) Distance (time frame: At baseline (1 week after catheter ablation) and within 1 week after completion of the 12-week intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07808307, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.